Business
SCYNEXIS to Present Ibrexafungerp Data at the 33rd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) April 15-18 in Denmark
JERSEY CITY, N.J., April 13, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and
About this update from Scynexis, Inc.
[{"type":"text","content":"JERSEY CITY, N.J., April 13, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of interim data across a diverse array of infection types from its ongoing Phase 3 FURI and CARES studies, as well as the innovative study design of its ongoing Phase 3 MARIO trial of oral ibrexafungerp treatment after an intravenous (IV) echinocandin, at the 33rd Annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) being held in Copenhagen, Denmark, April 15-18, 2023. Oral e-Poster Presentation: Title: Outcomes of Oral Ibrexafungerp in Subjects with Urinary Tract Infections from Two Phase 3 Open-Label Studies: Difficult-To-Treat Invasive Fungal Infections (FURI) and Infections with Candida auris (CARES)Session: Oral e-Poster Flash Session (EF121): Arena 3: Fungal treatments around the worldDate: April 16Session Time: 1:30 p.m. – 2:30 p.m. CET / 7:30 a.m. – 8:30 a.m. EDTPresentation Time: 1:48 p.m. CET / 7:48 a.m. EDT Presenter: Nkechi Azie, M.D., FIDSA (New Jersey, United States) Poster Presentations: Title: Evaluation of the Effect of Ibrexafungerp Alone and in Combination with Amphotericin B or Posaconazole against Mucor Strains on Time Kill Kinetics and Scanning Electron MicroscopyPoster Session 6C: Antifungal susceptibility testing & resistance (incl. surveillance)Poster: P2020Date: April 16Time: 12:00 p.m. – 1:30 p.m. CET / 6:00 a.m. – 7:30 a.m. EDTPresenter: Mahmoud Ghannoum, Ph.D. (Ohio, United States) Title: A Novel Protocol Design to Study the Efficacy and Safety of Oral Ibrexafungerp as Step-Down Therapy Following Intravenous (IV) Echinocandin for the Treatment of Invasive Candidiasis (MARIO): Developing a Paradigm Shift to IV and Oral Anti-Cell Wall TherapyPoster Session 6D: Antifungal drugs & treatment (incl. clinical trials)Poster: P2055Date: April 16Time: 12:00 p.m. – 1:30 p.m. CET / 6:00 a.m. – 7:30 a.m. EDTPresenter: Thomas Walsh, M.D., Ph.D. (hon) (Virginia, United States) Title: Oral Ibrexafungerp FURI Study: Outcomes in Subjects with Intraabdominal Candidiasis Poster Session 6D: Antifungal drugs & treatment (incl. clinical trials)Poster: P2068Date: April 16Time: 12:00 p.m. – 1:30 p.m. CET / 6:00 a.m. – 7:30 a.m. EDTPresenter: Philipp Ko...